June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab and/or intravitreal dexamethasone implant
Author Affiliations & Notes
  • Antoine Herbaut
    93000, Avicenne hospital of Bobigny, Paris, France
  • Lise Qu Knafo
    93000, Avicenne hospital of Bobigny, Paris, France
  • Audrey Giocanti Auregan
    93000, Avicenne hospital of Bobigny, Paris, France
  • Franck Fajnkuchen
    93000, Avicenne hospital of Bobigny, Paris, France
  • Footnotes
    Commercial Relationships   Antoine Herbaut, None; Lise Qu Knafo, None; Audrey Giocanti Auregan, None; Franck Fajnkuchen, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1891. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Antoine Herbaut, Lise Qu Knafo, Audrey Giocanti Auregan, Franck Fajnkuchen; Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab and/or intravitreal dexamethasone implant. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1891.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The aim of this study was to evaluate the short-term functional and anatomical outcomes following conversion from ranibizumab or dexamethasone therapy to aflibercept for the treatment of refractory Diabetic Macular Edema (DME).

Methods : We conducted a retrospective study in a real life setting, including eyes with persistent DME after at least 3 injections of ranibizumab and/or one intravitreal dexamethasone implant. All patients received a loading dose of 3 injections of aflibercept and treated on an as-needed regimen. Our primary endpoint was the mean variation of visual acuity (VA) at 6 months of follow-up.

Results : 25 eyes of 21 patients were included. Before aflibercept conversion, 23 eyes received a median number of ranibizumab of about 9 injections and among them, 6 eyes received dexamethasone implant after ranibizumab. 2 eyes received one dexamethasone implant only before conversion to aflibercept. The mean follow-up was of 5.7 months. Baseline VA was of 57.1 + 19.6 letters. The mean gain of VA was +8 letters at 6 months of follow-up (p=0.006). The mean central retinal thickness (CRT) was 470.8 + 129.9 μm prior to conversion (SD-OCT, Cirrus 5000, Zeiss, Meditec). At 6 months of follow-up, the CRT improved to 303.3 + 59.1 μm, with a mean decrease of -167.5+149.3 μm (p<0.001).66,6% of patients had a CRT<300 μm at 6 months of follow-up. In this subgroup, VA improved of +11.1 letters (p=0.02).

Conclusions : Conversion to aflibercept after prior ranibizumab and/or dexamethasone treatment of DME, resulted in significant functional and anatomical improvements.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×